Current treatment of Hodgkin's disease

被引:3
作者
Eghbali, H [1 ]
Soubeyran, P [1 ]
Tchen, N [1 ]
de Mascarel, I [1 ]
Soubeyran, I [1 ]
Richaud, P [1 ]
机构
[1] Inst Bergonie, Reg Canc Ctr, F-33076 Bordeaux, France
关键词
D O I
10.1016/S1040-8428(99)00070-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In spite of the fact that Hodgkin's disease (HD) remains still an enigma its management and treatment yield a cure rate of about 80% of all patients. However, this management has two limits: on one side favourable cases which should not be overtreated because of unacceptable side-effects, and on the other side very unfavourable cases which should be treated differently because of a very high rate of failure and/or relapse. Then it becomes necessary to precise as thoroughly as possible these two limits in order to choose the adequate treatment for the patient. Prognostic factors based on patient and disease characteristics allow a relatively exact classification of favourable and unfavourable cases. This distinction in two prognostic groups has therapeutic implications in terms of chemotherapy (regimen, duration) and radiotherapy (extension, doses). Other specific situations have to be considered, e.g. pediatric cases, pregnancy, old age and HIV-infected patients who need an adapted management according to very different situations. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:49 / 73
页数:25
相关论文
共 381 条
[1]   BONE-MARROW EXAMINATION IN HODGKINS-DISEASE [J].
ABRAHAMSEN, AF ;
JAKOBSEN, E ;
LANGHOLM, R ;
ABRAHAMSEN, JF ;
KVALOY, S ;
NOME, O .
ACTA ONCOLOGICA, 1992, 31 (01) :41-42
[2]  
Aisenberg AC, 1997, CANCER, V79, P1203, DOI 10.1002/(SICI)1097-0142(19970315)79:6<1203::AID-CNCR20>3.0.CO
[3]  
2-2
[4]  
AMBROSETTI A, 1993, CANCER, V72, P201, DOI 10.1002/1097-0142(19930701)72:1<201::AID-CNCR2820720136>3.0.CO
[5]  
2-V
[6]  
AMES ED, 1993, ANN INTERN MED, V118, P313, DOI 10.7326/0003-4819-118-4-199302150-00017
[7]   A RANDOMIZED STUDY OF ADJUVANT CHEMOTHERAPY AFTER MANTLE RADIOTHERAPY IN SUPRADIAPHRAGMATIC HODGKINS-DISEASE PS-IA-IIB - A REPORT FROM THE MANCHESTER LYMPHOMA GROUP [J].
ANDERSON, H ;
DEAKIN, DP ;
WAGSTAFF, J ;
JONES, JM ;
TODD, IDH ;
WILKINSON, PM ;
JAMES, RD ;
STEWARD, WP ;
BLACKLEDGE, G ;
SCARFFE, JH ;
CROWTHER, D .
BRITISH JOURNAL OF CANCER, 1984, 49 (06) :695-702
[8]   THE PROGNOSTIC-SIGNIFICANCE OF MEDIASTINAL BULK IN PATIENTS WITH STAGE IA-IVB HODGKINS-DISEASE - A REPORT FROM THE MANCHESTER LYMPHOMA GROUP [J].
ANDERSON, H ;
JENKINS, JPR ;
BRIGG, DJ ;
DEAKIN, DP ;
PALMER, MK ;
TODD, IDH ;
CROWTHER, D .
CLINICAL RADIOLOGY, 1985, 36 (05) :449-454
[9]  
ANDERSON JR, 1995, ANN ONCOL, V6, P167
[10]   HODGKINS-DISEASE DURING HIV-1 INFECTION - THE FRENCH REGISTRY EXPERIENCE [J].
ANDRIEU, JM ;
ROITHMANN, S ;
TOURANI, JM ;
LEVY, R ;
DESABLENS, B ;
LEMAIGNAN, C ;
GASTAUT, JA ;
BRICE, P ;
RAPHAEL, M ;
TAILLAN, B .
ANNALS OF ONCOLOGY, 1993, 4 (08) :635-641